Industry proposes measures to ensure France remains a hub of excellence in research and patient access to innovation
The tenth annual ‘Attractiveness of France for clinical research’ survey carried out by Les Entreprises du Médicament (LEEM) assesses clinical trials conducted by the industry between 2018 and 2019. The survey has been conducted every two years since 2002 to track and assess the position of France’s clinical research.
Based on the lessons of the COVID-19 pandemic and the results of the tenth annual survey on clinical trials, LEEM proposes measures to ensure France remains a hub of excellence for clinical research and continues to guarantee early access to innovations for all.
These include proposals to create a national platform for early trials, develop facilities dedicated to early access and measures to simplify the conduct of clinical trials.
For more information on the details of the proposals, please read the LEEM press release.